Months removed from an intercontinental M&A dance that polarized investors and paralyzed executives, Pfizer and AstraZeneca will soon be free to start talking about a deal once more, provided the latter company is interested.
Pfizer and Bristol-Myers Squibb's Eliquis has been lagging since launch time, trailing behind predecessors Pradaxa and Xarelto. But lately, the drugmakers' efforts have been paying off when it comes to market share, and a new indication may help keep the ball rolling.
Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's Enbrel in a head-to-head study.
Look under a pharma executive's bed, and you'll find monsters. What do those monsters look like, though? Accenture talked to C-suite executives at the world's biggest drugmakers and found that some of yesteryear's scary beings have moved on, leaving others to take front and center.
Pfizer is recalling two lots of its 40 mg/ mL, 1 mL single-dose vials of its anti inflammatory product Depo-Medrol.
Pfizer may not get a great shot at buying AstraZeneca this fall--but it's preparing to give it a try. Meanwhile, Bloomberg reports, the U.S.-based drug giant is looking at Actavis, the generics maker with a new home address in Ireland, among other targets.
When it comes to manufacturing, Big Pharma prefers traditional plants to living plants. While drugs manufactured from plants like tobacco have been in the news because several makers of Ebola drug candidates are using the process, the method has not been embraced by any of the major players.
As expected, Pfizer has submitted an early FDA application for palbociclib, beating a quick path to market with a breakthrough breast cancer treatment that could peak at nearly $3 billion a year.
Forget tax-advantaged Irish drugmakers. It may be a good time to take over an antibiotics maker on the cheap--and analysts have just the antibiotics maker in mind.
The Alabama Supreme Court won't back away from a controversial ruling against Pfizer, in a liability case closely watched by the rest of the pharma industry.